News & Updates
Showing Obstetrics & Gynaecology articles
Showing
Show Multimedia Only

Prexasertib works in select patients with recurrent ovarian cancer
14 Oct 2022
CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.
14 Oct 2022







